Bainuo Molecular Doctor Launches 'Precision Medicine Department v1.0', Pioneering a New Model in Precision Healthcare

Currently, healthcare is advancing toward the field of precision medicine. However, the implementation of precision medicine in hospitals faces significant challenges, with pain points such as physicians’ uncertainty in test selection and difficulties in interpreting diagnostic reports hindering its development. On July 4, Bainuo Molecular Doctor officially launched “Precision Medicine Department v1.0,” introducing functional modules including intelligent test recommendation, self-service selection options, treatment plan recommendations, and intelligent report interpretation. These features aim to address the current pain points and challenges in hospital-based precision medicine implementation.

In recent years, precision medicine has become a hot topic worldwide, triggering significant activity in capital markets and transforming hospital service models. Due to the lack of genetic testing platforms, testing products, and supporting precision medicine systems, many hospitals are unable to offer precision medicine services independently, relying instead on third-party precision medicine departments for testing. In this process, physicians face several challenges: Given the wide variety of third-party test panels, do the selected tests align with patients’ clinical diagnoses, health status, or family history? Will the third-party precision medicine testing proceed smoothly? When will the test reports be available? Furthermore, physicians may encounter questions regarding report content, such as unclear drug recommendations, detailed drug information, clinical guidance significance, and the implications of specific mutations. Patients and their families also harbor concerns about whether the testing holds clinical guidance value, and whether there are issues such as ambiguous medication instructions or unknown risks.

Breaking away from traditional diagnostic and treatment models, Bainuo builds an intelligent molecular medicine technology platform for hospitals, creating a dedicated "Molecular Physician" for each patient. By closely integrating precision medicine knowledge with artificial intelligence technologies, and leveraging a cutting-edge knowledge base for oncology and chronic diseases alongside advanced platforms for precise diagnosis, analysis, and interpretation, Bainuo enables patients to receive timely, internationally standardized precision medical services. It empowers physicians with molecular diagnostic capabilities and enhances hospitals’ precision medicine proficiency, working hand in hand with healthcare institutions to drive the transformation of China’s precision medicine industry.

At this press conference, Bonao Medical made a major announcement with the launch of Molecular Doctor “Precision Medicine Department v1.0.” Dr. Liu Xin, Director of Genetic Counseling at Bonao Medical, provided an in-depth and comprehensive introduction to Bonao’s Molecular Doctor “Precision Medicine Department v1.0,” contextualized within the current development of precision medicine. “By leveraging Bonao’s three core application models—precision testing, precision interpretation, and precision implementation—and integrating artificial intelligence and big data technologies, along with multidimensional expert insights from the fields of molecular biology, clinical practice, AI, and big data, we empower hospitals to apply precision medicine across disease prevention, treatment, medication management, and rehabilitation. Furthermore, tailored to each hospital’s unique characteristics, we help institutions build their own precision medicine technology systems, enhance their international capabilities in precision medicine, strengthen their core competitiveness, and ultimately benefit more patients.”

“Precision Medicine Department” Service Model

As a one-stop precision medicine service platform, Bino Molecular Doctor’s “Precision Medicine Department v1.0” provides comprehensive coverage spanning product selection, order confirmation, order tracking, report downloading, detailed report interpretation, and content consultation. Furthermore, it enables the one-on-one establishment of precision medicine departments tailored to the specific configurations and unique characteristics of individual hospitals, thereby creating exclusive, personalized precision medicine services for each institution. Currently, Precision Medicine Department v1.0 can accurately screen or recommend appropriate testing items based on patients’ health status or disease information, ensuring a high degree of matching. Additionally, the platform employs a real-time online operating system that is time-saving, labor-efficient, and user-friendly, while offering transparent information and timely feedback, allowing users to track testing progress at any time. Both physicians and patients can conveniently access report contents and extended knowledge resources, with secondary interpretations and online consultations readily available. Most importantly, leveraging its extensive medical knowledge base integrated with artificial intelligence and big data technologies, Bino Molecular Doctor empowers hospitals to apply precision medicine in disease prevention, treatment, medication management, and rehabilitation, thereby facilitating clinical breakthroughs in major specific diseases such as lung cancer, liver cancer, and breast cancer, as well as in chronic disease management.

Precision medicine is an inevitable trend in the development of medicine itself. Its clinical applications—such as in oncology, whole-course precision management, susceptibility gene risk analysis, early screening, molecular subtyping-guided precision care, and precise tumor treatment—have already positioned precision medicine at the forefront. In response to the four core competitive pillars of current healthcare services—accurate diagnosis, effective treatment, safe medication, and technical capability—hospitals can leverage the “Molecular Doctor: Precision Medicine Department v1.0” platform to advance diagnostic and therapeutic practices from a precision medicine perspective.

At the press conference, Ma Weijin, President of Bainuo Company, stated, “Over the next decade, precision medicine departments will become essential clinical units for hospital development. Empowering hospitals with globally synchronized precision medicine capabilities is the foundational principle behind Bainuo Medical’s construction of the ‘Molecular Doctor’ platform. Our consistent focus has been on enabling hospitals to acquire precision medicine capabilities in the simplest possible manner. The launch of the ‘Molecular Doctor’ platform will advance the development of precision medicine capabilities across the entire healthcare industry and usher in a new medical paradigm for human health. Currently, Bainuo is establishing the first batch of demonstration ‘Precision Medicine Departments’ with Shenzhen as its base, and will rapidly expand this model from pilot sites to cover major specialized hospitals nationwide.”